Johnson & Johnson MedTech (J&J MedTech), the medical technology company of Johnson and Johnson (J&J), has signed an exclusive US commercial distribution agreement with Responsive Arthroscopy.
Responsive Arthroscopy is a US-based medical device company specialising in sports soft tissue repair solutions for various joints, including the knee, shoulder, hip, foot, and ankle.
Its products focus on sports medicine, such as its Thunderbolt Syndesmosis Implant System to treat high ankle sprains or isolated syndesmosis injuries to the ankle.
The partnership will combine J&J MedTech’s expertise in orthopaedics with Responsive Arthroscopy’s advanced technologies to help healthcare providers respond to evolving needs.
J&J MedTech said the distribution agreement with Responsive Arthroscopy will strengthen its sports platform and enhance its soft tissue portfolio.
The agreement will also help address the increasing demand for advanced solutions in the growing sports soft tissue repair market, said the medical device company.
Johnson & Johnson MedTech orthopaedics group chairman Aldo Denti said: “Our relationship with Responsive Arthroscopy is a significant step in expanding our leadership in orthopaedics and advancing our sports soft tissue offerings.
“This collaboration allows us to deliver a broader range of cutting-edge tools that empower surgeons in shoulder, foot and ankle procedures.
“We’re excited to drive value in this rapidly growing segment and remain committed to advancing patient care in meaningful ways.”
Recently, J&J MedTech received the US Food & Drug Administration (FDA) approval for its Varipulse platform to treat drug-refractory paroxysmal Atrial Fibrillation (AFib).
The Varipulse platform is a pulsed field ablation (PFA) system that comprises the Varipulse Catheter, Trupulse Generator, and CARTO 3 Mapping System.
CARTO 3 is a 3D electro-anatomical cardiac mapping system that enhances mapping capabilities to simplify procedures, reduce procedure time, and improve outcomes.
The FDA approval is based on the data from the admIRE study, a multi-centre, non-randomised clinical trial in 291 patients across 30 healthcare centres in the US.
